Common to all MASLD patients is the repression of the glucose transporters SLC2A1 and SLC2A2 while the fructose transporters SLC2A8 and SLC2A9 were significantly up‐regulated (Figures 4B and S5A). Here, SLC2A5 is linked to metabolic dysfunction-associated steatotic liver disease.